Laboratory Research
Tx Group Treatment (FD = Film Dressing) Application (days) Animal Codes “n” Day 35 Harvest Day 63 Harvest 1 Film Dressing Only (Negative Control) 0, 4 ,8, 12 & 16 JELL-02.01 to 02.08 JELL-02.09 to 02.12 12 2 Micronized cross-linked CT0 powder + FD (2.5mg aliquot) Day 0 only JELL-02.25 to 02.32 JELL-02.33 to 02.36 12 3 Micronized chemically modified CT0 powder + FD (2.5mg aliquot) Day 0 only JELL-02.37 to 02.44 JELL-02.44 to 02.48 12 4 Bovine collagen comparator Day 0 only JELL-02.49 to 02.56 JELL-02.57 to 02.60 12
Methods: Treatment Regimens
Overall wound closure, contribution of wound contraction, and wound re-epithelialisation was determined. Histological investigations (days 35 and 63) investigated: i) % re-epithelialisation, ii) granulation formation and iii) tissue response and integration.
Results:
Wound Healing: From day 12 to day 49, crosslinked and chemically modified CT0 powders demonstrated significantly increased levels of wound closure (p≤0.029 & p≤0.024 respectively), contraction (p≤0.029) and promoted re-epithelialisation with significantly increased re-epithelialisation observed vs bovine with the chemically modified CT0 powder on day 8 (p=0.010).
Discussion:
Histology:
Re-epithelialisation & Granulation: All treatments were found to encourage better re-epithelialisation and granulation relative to control (film dressing only). Tissue formation via bovine collagen tended to be less mature with higher numbers of inflammatory cells compared to CT0
Assessment of tissue ingress & cellular profile: CT0 powders demonstrated better vascularisation, host collagen deposition & cellular proliferation compared to the bovine comparator.
Conclusions/
Discussion: Jellyfish collagen offers exciting potential as an effective biomaterial to heal wounds with a better quality of outcome and favoured immune response. Compared to bovine collagen, CT0 upregulated a preferred granulation tissue being more uniform and mature. Interestingly, CT0 also appeared not to contract the wound offering a potential clinical benefit.